Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Osimertinib-tolerant lung cancer cells are susceptible to ferroptosis.

Biochemical and biophysical research communications - 22 Jan 2023

Konishi Hiroto, Haga Yuya, Lin Ying, Tsujino Hirofumi, Higashisaka Kazuma, Tsutsumi Yasuo

Abstract excerpt

Tyrosine kinase inhibitors of epidermal growth factor receptor (EGFR-TKIs), such as osimertinib, show great success in non-small-cell lung cancer patients with EGFR mutated tumors. However, almost all patients develop resistance to EGFR-TKIs owing to secondary EGFR mutations. Although genetic and irreversible resistance mechanisms have been proposed, little is known about non-genetic and reversible resistance...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to ErbB Receptors

Share to Ferroptosis

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 36527745
DOI: 10.1016/j.bbrc.2022.12.029

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Osimertinib-tolerant lung cancer cells are susceptible to ferroptosis.PMID 36527745Read ↗

Targeting of drug-tolerant persister cells as an approach to counter drug resistance in non-small cell lung cancer.Semantic proximity Read ↗

Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Nanotechnology-integrated ferroptosis inducers: a sharp sword against tumor drug resistanceSemantic proximity Read ↗

Insights Into Ferroptosis, a Novel Target for the Therapy of CancerSemantic proximity Read ↗

Identification of a set of genes potentially responsible for resistance to ferroptosis in lung adenocarcinoma cancer stem cellsSemantic proximity Read ↗

TP63 drives TKI resistance in EGFR-mutant lung cancer via ferroptosis inhibition.Semantic proximity Read ↗

Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapySemantic proximity Read ↗

Identification of a set of genes potentially responsible for resistance to ferroptosis in lung adenocarcinoma cancer stem cellsSemantic proximity Read ↗

In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma.Semantic proximity Read ↗

Induction of Ferroptosis by an Amalgam of Extracellular Vesicles and Iron Oxide Nanoparticles Overcomes Cisplatin Resistance in Lung CancerSemantic proximity Read ↗

The EGFR inhibitor osimertinib promotes a dynamic Drug Tolerant Persister state marked by replication defects and genome instabilitySemantic proximity Read ↗

The Essential Roles of Exosome and CircRNA_101093 to Desensitize Lung Adenocarcinoma to FerroptosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.